Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (1111)	5/18/1999 7:36:00 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 10293

Hemispherx, another round. Just received a new edition of a domestic exchange newsletter (which had otherwise a quite good standing). A full page is dedicated to our old lady o roll, HEB, incredible: As always, a disclaimer is missing. Basic Points: -30 year-old company, not just a startup, unique over the world (tsk) -Market Cap of $140 Mio is treated "cheap" (!) -Ampligen mentioned: only 30% failure in treatment.., it is "rumoured" that an application in Europe is to expected "in short time". It should also be fast-acting against HIV. -"Analysts" (unnamed) calculated that a 1% market share (of the 2.5 Mill CFS patients) would give the company earnings of $1.60 -rumoured a Nasdaq and German New Market listing, which should increase the focus, and "hence" achieve a "fair valuation". -comparable companies valued 3x more expensive (but no other companies named, and no measurement criteria given) The articles closes with a "speculative buy" rating, but buyers should use a S/L of $5. ... Buyers, beware IS.com